cemsidomide (CFT7455) / C4 Therap - LARVOL DELTA

T- and NK-Cell Immunomodulatory Reprogramming by Cemsidomide, a Novel and Potent MonoDAC® Degrader, in Relapsed/Refractory Multiple Myeloma: Biomarker Results from CFT7455–1101 Arm B2 Cohort (IMS 2026) - "Cemsidomide is a novel, highly potent oral Cereblon-based IKZF1/3 MonoDAC ® degrader with retained activity in lenalidomide- and pomalidomide-resistant models. Cemsidomide with dexamethasone combination produced a coherent cyclical immune reprogramming signature with IL2-led Th1 cytokine induction concordant with broad CD4+ and CD8+ T-cell activation, expansion of non-senescent armed CD8+ effectors, and dose-dependent NK cytotoxic enhancement with maintained CD314 expression. The clinical response during CFT7455-1101 supports continued development, including evaluation in combination with T-cell and other immune-based therapies."

Biomarker • Immunomodulating • IO biomarker • Hematological Malignancies • Multiple Myeloma • B3GAT1 • CD14 • CD38 • CD4 • CD8 • CRBN • GZMB • IFNG • IKZF1 • NKG2D • PRF1 • TNFA

Phase 1b Trial of Cemsidomide in Combination with Elranatamab (GlobeNewswire) - "Biomarker data from the first two patients showed that cemsidomide drives the expansion and activation of CD8+ effector memory T cells as measured by elevated HLA-DR and prevents T-cell exhaustion as measured by PD-1, TIM-3 and LAG3 expression....In addition, following the completion of the first safety cohort evaluating six patients, the safety data review committee declared the 75 µg cemsidomide dose level in combination with elranatamab safe. The Phase 1b trial is now advancing into a dose escalation safety cohort at the 100 µg cemsidomide dose level and an expansion cohort at the 75 µg cemsidomide dose level. Data from all cohorts evaluated in the Phase 1b trial are expected in mid-2027."

Biomarker • DSMB • P1 data • Trial status • Multiple Myeloma

Phase 1 Trial of Cemsidomide in Combination with Dexamethasone (GlobeNewswire) - "In 62 heavily pre-treated RRMM patients across the once-daily (QD) dose levels, cemsidomide demonstrated coordinated activation of T cells, including CD8+ T cells, and functional reprogramming of natural killer (NK) cells. Notably, enhanced immune cell function was observed at the highest dose levels studied (75 µg and 100 µg), which also achieved compelling overall response rates in the Phase 1 trial."

P1 data • Multiple Myeloma

Updated Results of a Phase 1 First-in-Human Study of Cemsidomide (CFT7455), a Novel MonoDAC® Degrader, with Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) (IMS 2025) - P1 | "MM eligible pts must have received lenalidomide, pomalidomide, a proteasome inhibitor, and an anti-CD38 antibody. Cemsidomide with DEX demonstrates compelling efficacy and tolerability as an all-oral therapy in a heavily pre-treated RRMM population, the majority of whom had received a CAR-T or bispecific antibody. Grade 3-4 toxicities consist largely of cycle 1-2 myelosuppression, which has been manageable with limited dose reductions and discontinuations. 100 ug is the maximum administered dose for planned further development."

Clinical • First-in-human • P1 data • Anemia • Febrile Neutropenia • Hematological Disorders • Hematological Malignancies • Infectious Disease • Multiple Myeloma • Neutropenia • Thrombocytopenia • CRBN • IKZF1 • IKZF3

ISABELA: A phase 2 study of isatuximab, belantamab mafodotin, pomalidomide, and dexamethasone in relapsed/refractory multiple myeloma. (ASCO 2026) - P2 | " ISABELA is an investigator-initiated study (NCT05922501) enrolling up to 50 patients (pts) with RRMM who have received at least 1 prior line of therapy including lenalidomide and a proteasome inhibitor...Prior therapies included pom (59%), bortezomib (82%), carfilzomib (41%), ixazomib (35%), CD38 antibody (59%) [daratumumab, 59%; isa 12%], and auto SCT (24%). Prior exposure to newer therapies included drugs that target BCMA (24%) [teclistamab 6%, elranatamab 18%, CAR T-cells 12%]; GPRC5D (12%) [talquetamab]; and cereblon (29%) [mezigdomide, 29%; cemsidomide, 12%]... This is the first report in RRMM for the combination of belamaf with a CD38 monoclonal antibody. The ISABELA regimen shows promising preliminary activity in RRMM with an ORR of 86% and 16-month PFS of 73%, including quad-class-exposed pts treated with anti-BCMA therapy, with manageable, reversible AEs."

P2 data • Cardiovascular • Hematological Malignancies • Hypertension • Infectious Disease • Multiple Myeloma • Neutropenia • Ophthalmology • Plasmacytoma • Thrombocytopenia • CRBN

Initial Results of a Phase 1 First-in-Human Study of Cemsidomide (CFT7455), a Novel MonoDACTM Degrader, with Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (ASH 2024) - P1 | "Eligible MM pts must have received lenalidomide, pomalidomide, a proteasome inhibitor, and an anti-CD38 antibody. Dose escalation will continue until an MTD and/or the recommended phase 2 doses are identified. Updated data will be presented at the conference."

Clinical • First-in-human • P1 data • Anemia • Fatigue • Hematological Disorders • Hematological Malignancies • Infectious Disease • Lymphoma • Multiple Myeloma • Neutropenia • Non-Hodgkin’s Lymphoma • Oncology • Thrombocytopenia • CRBN • IKZF1 • IKZF3

MOMENTUM: A phase 2, open-label, single-arm, multicenter study to evaluate the efficacy of cemsidomide + dexamethasone in subjects with relapsed/refractory multiple myeloma (RRMM). (ASCO 2026) - P2 | "A safety review committee and an IRC will be established to oversee safety and efficacy throughout the trial. The study is open to enrollment as of December 2025."

Clinical • IO biomarker • P2 data • Hematological Malignancies • Multiple Myeloma • Targeted Protein Degradation • CRBN • IKZF1

A poster presentation was accepted at the International Myeloma Society (IMS) Annual Meeting, featuring additional biomarker data on cemsidomide’s immunomodulatory effects on T cells and natural killer (NK) cells in combination with dexamethasone. (C4 Therapeutics Press Release) - "These data further support cemsidomide’s potential as a combination partner for immune-based therapies."

Biomarker • P1/2 data • Multiple Myeloma

Study start-up activities are underway for an additional Phase 1b trial evaluating cemsidomide across two treatment arms for relapsed refractory MM patients: (C4 Therapeutics Press Release) - "(1) cemsidomide, dexamethasone, daratumumab, a CD38 antibody, and (2) cemsidomide, dexamethasone, carfilzomib, a proteasome inhibitor. The trial is expected to initiate in the first half of 2027 with the goal to characterize cemsidomide’s dose and safety with approved standard of care MM therapies."

New P1 trial • Multiple Myeloma

SECOND QUARTER 2026 UPDATES AND RECENT ACHIEVEMENTS (C4 Therapeutics Press Release) - "The ongoing Phase 2 MOMENTUM trial evaluating cemsidomide in combination with dexamethasone in late-line multiple myeloma (MM) treatment is on track to complete enrollment in the first quarter of 2027. The initial investigator-assessed overall response rate (ORR) data are expected in the second half of 2027. The ongoing Phase 1b trial evaluating cemsidomide and dexamethasone in combination with elranatamab (ELREXFIO), a B-cell maturation antigen CD3 targeted bispecific antibody, in earlier lines of MM treatment continues to progress. C4T expects to provide an update on the dose escalation progress in the second half of 2026 with data from all cohorts expected in mid-2027."

P1 data • P2 data • Trial status • Multiple Myeloma

UPDATED RESULTS OF A PHASE 1 FIRST-IN-HUMAN STUDY OF CEMSIDOMIDE, A NOVEL MONODAC® DEGRADER, WITH DEXAMETHASONE (DEX) IN PATIENTS WITH (RRMM) (EHA 2026) - P1, P2 | "Eligible MM pts must have received lenalidomide, pomalidomide, a proteasome inhibitor, and an anti-CD38 antibody. Further development includes a phase 2 MOMENTUM study (NCT07284758) and a phase 1 b study of cemsidomide and elranatamab (NCT07280013). Updated safety and antimyeloma endpoints will be presented at the conference."

Clinical • First-in-human • IO biomarker • P1 data • Febrile Neutropenia • Hematological Disorders • Hematological Malignancies • Infectious Disease • Leukopenia • Multiple Myeloma • Neutropenia • Pneumonia • Respiratory Diseases • Thrombocytopenia • CRBN • IKZF1 • IKZF3

MOMENTUM: A PHASE 2, OPEN-LABEL, SINGLE-ARM, MULTICENTER STUDY TO EVALUATE THE EFFICACY OF CEMSIDOMIDE + DEXAMETHASONE IN SUBJECTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (EHA 2026) - P2 | "A safety review committee and an IRC will be established to oversee safety and efficacy throughout the trial. Results The study is open to enrollment as of December 2025 and is currently recruiting."

Clinical • IO biomarker • P2 data • Hematological Malignancies • Multiple Myeloma • Targeted Protein Degradation • CRBN • IKZF1

C4 Therapeutics Presents Phase 1 Data at European Hematology Association (EHA) 2026 Congress Highlighting Cemsidomide as a Potential Best-in-Class IKZF1/3 Degrader for Multiple Myeloma in Heavily Pretreated Relapsed/Refractory Population (GlobeNewswire) - "The poster presentation includes data on 73 patients with a data cutoff of February 27, 2026....At the RP2D and maximum tolerated dose (100 µg,) cemsidomide achieved a 53% overall response rate (ORR). At the 75 µg dose level, cemsidomide achieved a 40% ORR. Across all doses evaluated, cemsidomide achieved a 36% ORR....At 75 µg, one patient whose best response was previously a partial response (PR) deepened to a very good partial response (VGPR). At 100 µg, several patients achieved a deeper response: One patient whose best response was previously a PR deepened to a stringent complete response (sCR). One patient whose best response was previously a PR deepened to a VGPR. Minimal residual disease (MRD) negativity was achieved in two patients who achieved a sCR and complete response (CR) at 100 µg."

P1 data • Multiple Myeloma

CFT7455-2101: A study of cemsidomide and dexamethasone in subjects with relapsed or refractory multiple myeloma (r/r MM) (clinicaltrialsregister.eu) - P1/2 | N=43 | Not yet recruiting | Sponsor: C4 Therapeutics Inc.

New P1/2 trial • Hematological Malignancies • Multiple Myeloma • Oncology

Upcoming milestones (Yahoo Finance) - "2H 2026: Provide an update on the dose escalation progress from the Phase 1b trial evaluating the combination of cemsidomide, dexamethasone, and elranatamab; By year-end 2026: Deliver at least one development candidate to a collaboration partner and advance collaborations toward key milestones."

Pipeline update • Trial status • Multiple Myeloma

C4 Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights (Yahoo Finance) - "Additional Phase 1b Trial Evaluating Cemsidomide in Combination with Approved Multiple Myeloma Therapies Expected to Initiate in the First Half of 2027."

New P1 trial • Multiple Myeloma

FIRST QUARTER 2026 HIGHLIGHTS AND RECENT ACHIEVEMENTS (Yahoo Finance) - "Data from the Phase 1 trial evaluating cemsidomide in combination with dexamethasone in RRMM was accepted as a poster presentation at the European Hematology Annual (EHA) Congress taking place from June 11 – June 14, 2026, in Stockholm, Sweden. Enrollment was completed in September 2025, and the poster presentation will include further analysis from the ongoing trial...A trial-in-progress poster highlighting the Phase 2 MOMENTUM trial evaluating cemsidomide in combination with dexamethasone in RRMM was accepted at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting taking place from May 29 – June 2, 2026, in Chicago, Illinois...The trial is expected to enroll approximately 100 patients and is on track to complete enrollment by the end of Q1 2027."

P1 data • Trial status • Multiple Myeloma

DAC-002, a novel IKZF1/3 MGD-CD38 degrader-antibody conjugate for MM treatment (AACR 2026) - "Notably, since IKZF1/3 are essential transcription factors (TFs) for the differentiation of B and T lymphocytes, single-agent IMiD therapy is hampered by a limited therapeutic window: as next-generation IMiDs (e.g., iberdomide, mezigdomide, cemsidomide) exhibit enhanced IKZF1/3 degradation activity, the incidence of grade ≥ 3 hematologic treatment-emergent adverse events (TEAEs) is correspondingly elevated...Degrader-Antibody conjugates (DACs) was generated by conjugation of CY001-80 (payload) to daratumumab monoclonal antibody (anti-CD38) using an optimized cleavable linker...In summary, DAC-002 is an highly potent IKZF1/3 MGD-CD38 DAC. In MM-H929 xenograft tumor model, DAC-002 treatment lead to robust tumor growth inhibition. No obvious safety concerns were observed in the preliminary NHP toxicology study."

IO biomarker • Late-breaking abstract • Hematological Malignancies • Multiple Myeloma • Oncology • IKZF1

C4 Therapeutics Announces First Patient Dosed in Phase 1b Trial of Cemsidomide in Combination with Elranatamab (ELREXFIO) for Relapsed/Refractory Multiple Myeloma (GlobeNewswire) - "Phase 1b data from all cohorts evaluating cemsidomide in combination with elranatamab is anticipated in mid-2027....The Phase 1b trial is part of a broader developmental strategy to support cemsidomide’s use across multiple lines of treatment. This strategy also includes the ongoing Phase 2 MOMENTUM Trial investigating the use of cemsidomide and dexamethasone in the fourth line of treatment or later. In addition to these two trials, C4T intends to evaluate cemsidomide in combination with other anti-myeloma agents, and remains on track to share these plans in mid-2026."

P1 data • Trial status • Multiple Myeloma

CFT7455-1101: Study to Assess the Safety and Tolerability of CFT7455 in Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma (clinicaltrials.gov) - P1 | N=224 | Active, not recruiting | Sponsor: C4 Therapeutics, Inc. | Trial completion date: Mar 2026 ➔ Dec 2026 | Trial primary completion date: Dec 2025 ➔ Sep 2026

Trial completion date • Trial primary completion date • Follicular Lymphoma • Hematological Malignancies • Lymphoma • Multiple Myeloma • Non-Hodgkin’s Lymphoma • Oncology • Peripheral T-cell Lymphoma

ANTICIPATED UPCOMING MILESTONES (GlobeNewswire) - "Phase 1b trial of cemsidomide in combination with elranatamab is on track to initiate in Q2 2026. Further analysis of the completed Phase 1 trial of cemsidomide in combination with dexamethasone is expected in mid-2026."

First-in-human • P1 data • Trial status • Multiple Myeloma

C4 Therapeutics Announces First Patient Dosed in Phase 2 MOMENTUM Trial of Cemsidomide, an Oral IKZF1/3 Degrader, in Combination with Dexamethasone for Relapsed/Refractory Multiple Myeloma (GlobeNewswire) - "Enrollment for Phase 2 MOMENTUM Trial Expected to Be Completed in Q1 2027."

Trial status • Multiple Myeloma

A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects (clinicaltrials.gov) - P1 | N=60 | Recruiting | Sponsor: C4 Therapeutics, Inc. | Not yet recruiting ➔ Recruiting

Enrollment open • Hematological Malignancies • Multiple Myeloma • Oncology

MOMENTUM: A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov) - P2 | N=100 | Recruiting | Sponsor: C4 Therapeutics, Inc. | Not yet recruiting ➔ Recruiting

Enrollment open • Hematological Malignancies • Multiple Myeloma • Oncology

2025 Achievements: Cemsidomide (GlobeNewswire) - "Completed enrollment in the Phase 1 trial of cemsidomide and dexamethasone and presented data demonstrating that the two highest dose levels (75 µg and 100 µg) achieved a 40% and 53% ORR, respectively. This compelling anti-myeloma activity in a heavily pretreated patient population reinforces cemsidomide’s potential best-in-class profile. Developed a regulatory path incorporating FDA feedback that positions cemsidomide to potentially receive two distinct accelerated approvals in (1) fourth line or later for cemsidomide and dexamethasone, and (2) second line or later for cemsidomide in combination with a BCMA BiTE. Selected 100 µg dose for the MOMENTUM trial as the recommended Phase 2 dose after discussions with FDA."

Enrollment closed • FDA event • P1 data • Multiple Myeloma